2344. FDA analysis of CD4+ cell count declines observed in HIV-infected children treated with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
Session: Poster Abstract Session: Pediatric Viral Infections
Saturday, October 6, 2018
Room: S Poster Hall
Posters
  • Science Poster - IDSA CD4 declines final 9-27-18.pdf (422.3 kB)
  • Background:

    Elvitegravir(EVG)/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) is approved for treatment of HIV-1 in children weighing ≥25 kg based on a Gilead sponsored study of safety, pharmacokinetics (PK), and antiviral activity among 23 virologically suppressed (VS) children 6-<12 years old who switched from a stable antiretroviral (ARV) regimen to E/C/F/TAF. All subjects were perinatally infected with HIV. Though all subjects maintained HIV viral load < 50 copies/mL, a decrease in mean CD4+ cell count (CD4ct) occurred at Week (Wk) 2 and persisted to Wk 24 (Table 1). 

    Table 1 Mean Change in CD4ct* from Baseline (BL) to Wk 24

     

    Change from BL

    Baseline (SD)

    Wk 2

    Wk 12

    Wk 24

    966 (201.7)

    -162

    -162

    -150

    * cells/µl

    Methods:  

    We explored possible reasons for CD4ct declines including change in overall leukocyte and absolute lymphocyte count (ALC), relationship between CD4ct and PK of each drug in E/C/F/TAF, and trends in subject-level CD4ct. We reviewed prior ARV trials and literature to look for drug class effects.

    Results:  

    Decreased CD4cts were not explained by declines in total leukocyte counts or ALC. There was no association between CD4ct and area under the curve (AUC) of any of the four drugs.   Mean CD4ct decline was not driven by a few outliers; CD4ct declined in 21/23 subjects. Prior ARV trials of VS adults and children, including EVG-containing regimens, show no notable sustained decline in CD4ct.  Pediatric studies of other integrase inhibitors (INSTI) in this age group did not have comparable VS subjects.  The literature describes structural similarity between human recombinant activation gene (RAG)1/2 and HIV integrase.  RAG inhibition by INSTIs could potentially interfere with B and T cell development.  EVG exposure in mice at supra-therapeutic concentrations, caused significant reductions in mature B lymphocytes. The relevance of this finding to humans is unclear.

     

    Conclusion:

    Decreased CD4ct is a unique finding in this pediatric study of E/C/F/TAF and the etiology remains unclear. Inhibition of RAG1/2 by EVG may play a role, but further research is needed.  No subjects had nadir CD4ct < 350 and no opportunistic infections were reported. However, CD4 declines are included in E/C/F/TAF labeling to alert providers of this potential risk.

     

    Tanvir Bell, MD, Melisse Baylor, MD, Sung Rhee, PhD, LaRee Tracy, MA, PhD, Mario Sampson, PharmD, Islam Younis, PhD, Yodit Belew, MD, Wendy Carter, DO and Prabha Viswanathan, MD, Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD

    Disclosures:

    T. Bell, None

    M. Baylor, None

    S. Rhee, None

    L. Tracy, None

    M. Sampson, None

    I. Younis, None

    Y. Belew, None

    W. Carter, None

    P. Viswanathan, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.